CureDuchenne Ventures, the venture funding arm of CureDuchenne, announces the CureDuchenne Ventures 2020 Pitch Contest.

The goal is to continue to find and support innovations in Duchenne therapy development, despite COVID-19 restricting the research community’s ability to meet in person at conferences and workshops. 

“While we have a long history of investments in early-stage Duchenne companies, we are expanding our model to create no-strings attached awards,” CEO and Founder of CureDuchenne, Debra Miller, says in a media release. “We are most interested in new therapeutic targets, as well as novel solutions for overcoming limitations of therapies currently in development, such as immune-targeting approaches to make gene therapy more widely accessible.”

The contest is open to US colleges, universities, biotech companies, and pharma companies with researchers in academia or industry focused on therapeutic targets and technology platforms that can be applied to Duchenne muscular dystrophy.

To enter, visit CureDuchenne. Each entry will consist of a brief application form and a slide presentation. Two winners will each be awarded $25,000, plus ongoing access to experts in the Duchenne drug discovery space to help provide strategic counsel and recommendations on next steps.

Submissions for the CureDuchenne Ventures 2020 Pitch Contest will be received until July 13, 2020, and all applications meeting the eligibility criteria will be evaluated to determine who will get invited to be finalists. 

Chosen finalists will virtually pitch their proposals live to the panel of judges. Pitches will be held between August 17 and 21, 2020, and up to eight applicants will be invited to participate. The winners will be announced in September 2020, per the release.

[Source(s): CureDuchenne, PR Newswire]